Is Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Kestra Medical Technologies, Ltd. at current levels.
The only credible challenger to ZOLL's wearable defibrillator monopoly, growing 60%+ with a better product and a wide-open market.
Where KMTS is headed
Kestra's bet is simple to state and hard to execute: take meaningful share in a wearable cardioverter defibrillator (WCD) market that ZOLL's LifeVest has owned, uncontested, for nearly two decades. By late 2027, Kestra should be running at $300M+ in revenue, gross margins pushing into the mid-50s as the ASSURE platform scales, and operating losses narrowing toward breakeven. That is the destination. The product itself is the reason it is plausible. ASSURE is lighter, more comfortable, has a smaller monitor, and the patient experience numbers (compliance, wear-time, returns) are materially better than LifeVest. Cardiologists who try it tend to keep prescribing it. That is the entire flywheel.
Read the full Compass Direction on KMTS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $19.92).
See the full KMTS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Kestra Medical Technologies, Ltd. at current levels. The only credible challenger to ZOLL's wearable defibrillator monopoly, growing 60%+ with a better product and a wide-open market.
What is KMTS's Compass Score?
Kestra Medical Technologies, Ltd. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for KMTS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the KMTS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.